DK1105102T3 - Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin - Google Patents

Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin

Info

Publication number
DK1105102T3
DK1105102T3 DK99936748T DK99936748T DK1105102T3 DK 1105102 T3 DK1105102 T3 DK 1105102T3 DK 99936748 T DK99936748 T DK 99936748T DK 99936748 T DK99936748 T DK 99936748T DK 1105102 T3 DK1105102 T3 DK 1105102T3
Authority
DK
Denmark
Prior art keywords
clopidogrel
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
ticlopidine
Prior art date
Application number
DK99936748T
Other languages
English (en)
Inventor
Thierry Breul
Claude Aleman
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK1105102T3 publication Critical patent/DK1105102T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DK99936748T 1998-08-20 1999-08-18 Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin DK1105102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810567A FR2782455B3 (fr) 1998-08-20 1998-08-20 Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
PCT/FR1999/002003 WO2000010534A1 (fr) 1998-08-20 1999-08-18 Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine

Publications (1)

Publication Number Publication Date
DK1105102T3 true DK1105102T3 (da) 2003-04-22

Family

ID=9529788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99936748T DK1105102T3 (da) 1998-08-20 1999-08-18 Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin

Country Status (9)

Country Link
EP (1) EP1105102B8 (da)
AT (1) ATE230258T1 (da)
AU (1) AU5173699A (da)
DE (1) DE69904727T2 (da)
DK (1) DK1105102T3 (da)
ES (1) ES2189456T3 (da)
FR (1) FR2782455B3 (da)
PT (1) PT1105102E (da)
WO (1) WO2000010534A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
WO2004112826A1 (en) 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
PL1847259T3 (pl) * 2006-04-13 2010-06-30 Acino Pharma Ag Poloksamery jako substancje smarne do kompozycji farmaceutycznych zawierających pochodne tieno [3,2-c]pirydyny
GB0804242D0 (en) * 2008-03-07 2008-04-16 Rosemont Pharmaceuticals Ltd Clopidogrel solution
EP2107061A1 (en) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
WO2009133455A2 (en) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Pharmaceutical composition of clodipogrel
FR2932387B1 (fr) * 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
WO2011071853A2 (en) * 2009-12-07 2011-06-16 Academic Pharmaceuticals Incorporated Parenteral formulation of clopidogrel
WO2011101865A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
WO2023012479A1 (en) 2021-08-03 2023-02-09 Liqmeds Worldwide Limited An oral pharmaceutical solution of clopidogrel
TW202339745A (zh) 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188870T1 (de) * 1994-10-04 2000-02-15 Lohmann Rudolf Lomapharm Lösungen von anthrachinonen zur parenteralen applikation
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable

Also Published As

Publication number Publication date
EP1105102B1 (fr) 2003-01-02
FR2782455B3 (fr) 2000-09-15
ES2189456T3 (es) 2003-07-01
EP1105102A1 (fr) 2001-06-13
ATE230258T1 (de) 2003-01-15
DE69904727D1 (de) 2003-02-06
AU5173699A (en) 2000-03-14
DE69904727T2 (de) 2003-11-13
FR2782455A1 (fr) 2000-02-25
EP1105102B8 (fr) 2003-08-06
PT1105102E (pt) 2003-04-30
WO2000010534A1 (fr) 2000-03-02

Similar Documents

Publication Publication Date Title
DK1105102T3 (da) Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
NO20061840L (no) Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
DZ2964A1 (fr) Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
ES2571852T3 (es) Moléculas mutantes CTLA4 solubles y usos de las mismas
AP2002002558A0 (en) Pharmaceutical compositions containing polymer and drug assemblies.
BRPI0407583A (pt) solução oftálmica lìmpida e estável
BRPI0414539B8 (pt) composto, composição farmacêutica, e, uso de um composto
DE50310649D1 (de) Gegen missbrauch gesicherte darreichungsform
EA200200954A1 (ru) Композиция
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
EP1438026A4 (en) TASTE-RELATED PROTECTIVE FORMULATION
ATE292453T1 (de) Antivirale arznei
BR0307448A (pt) Preparação liofilizada compreendendo imunocitocinas
ATE378070T1 (de) Zusammensetzung mit fulvestrant
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
NO980785L (no) Sulfonamidsubstituerte kondenserte 7-ringforbindelser, deres anvendelse som medikament samt farmasöytiske preparater inneholdende forbindelsene
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
DE60136064D1 (de) Wässrige flüssige preparation von pranoprofen
BR9911960B1 (pt) composição medicamentosa autoadesiva, e, utilização da mesma.
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
NO20004816L (no) Ny farmasøytisk formulering
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
BR0008241A (pt) Utilização de fanquinona para a preparação deuma composição farmacêutica para o tratamentode enfraquecimento de memória e método detratamento